ConductOrganoid

ConductOrganoid

Automated Morphological Phenotyping of Prenatal Opioid Exposure in Human Neural Organoids

A combinatorial in vitro/in silico NAM for quantifying how opioid exposure alters neurodevelopmental morphology. No animals required.

Explore Live ResultsTry It Yourself

1,407

Images Analyzed

64

Organoids Tracked

4

Cell Lines Compared

27/48

Significant Differences

Four Analysis Modules

A multi-modal combinatorial NAM from single-image morphology to electrophysiology and longitudinal dynamics.

ConductImage

Operational

2D Morphology from Brightfield Microscopy

Automated segmentation and feature extraction from standard brightfield images. No fluorescent labels required.

  • 16 features + 3 QC metrics per image
  • 9 morphology, 3 intensity, 4 texture features
  • Deterministic pipeline at 130 ms/image
  • Cross-lab reproducibility validated

ConductSignal

Phase 2

MEA/Calcium Electrophysiology

Multi-electrode array and calcium imaging analysis to correlate morphological phenotypes with functional network activity changes from opioid exposure.

  • Burst rate and spike frequency
  • Network synchrony metrics
  • Connectivity mapping
  • Functional-morphological correlation

ConductTrace

Phase 2

3D Confocal Neurite Topology

Skeletonization and graph-based analysis of neurite morphology from 3D confocal stacks.

  • Skeleton total length and branch length
  • Branch point and terminal tip counts
  • Topological complexity (Betti numbers)
  • Sholl analysis intersection profile

ConductVision

Phase 2

Time-Series Growth Dynamics

Longitudinal tracking of organoid growth, shape evolution, and phenotypic divergence over culture days.

  • Growth curves with exponential/logistic fits
  • Doubling time estimation
  • Trajectory clustering
  • Dose-response morphological curves

Key Finding

Our automated pipeline detects statistically significant morphological differences between wildtype and disease-model organoids across 27 of 48 feature-clone comparisons (p < 0.05, Bonferroni corrected, per-organoid aggregated N=16 per group), with effect sizes reaching |r| = 1.0.

Critically, the features that distinguish disease from wildtype — area, boundary integrity, tissue texture, and intensity heterogeneity — are the same endpoints that published opioid-organoid studies report as affected by prenatal opioid exposure. This establishes both analytical validity and biological plausibility for the target context of use.

Beyond Software: A Complete Testing System

ConductOrganoid is the intelligence layer of a complete, integrated developmental neurotoxicity testing system.

ConductChip

Hardware

Standard Protocol

Media kit

Any Microscope

Brightfield

ConductOrganoid

Analysis

Phase 3 delivers the full system. No organoid expertise needed.

Learn more about ConductChip

Regulatory Readiness

ConductOrganoid is designed for regulatory qualification under OECD Test Guideline 426. Explore our evidence:

NAM-vs-Animal Concordance

See how each ConductOrganoid feature maps to OECD TG 426 animal endpoints, with published evidence linking them.

View Dashboard

Context of Use Explorer

Interactive walkthrough of the regulatory pathway: what TG 426 requires, how we address it, and our validation roadmap.

Explore Pathway

Built on Real, Published Data

All analysis is performed on data from Zenodo 10301912 (Schröter et al., Scientific Data 2024) — 1,407 brightfield microscopy images from 64 organoids across 4 iPSC-derived cell lines (1 wildtype + 3 disease models).

No synthetic or simulated data. Every result shown on this site is derived from real experimental images.

NIH Complement-ARIE Reduction to Practice Challenge — Phase 1

A combinatorial in vitro/in silico NAM for automated neurodevelopmental phenotyping of prenatal opioid exposure in human neural organoids